SLC5A2 and diabetic kidney disease: In diabetic mice, SGLT2 inhibitors reduced albuminuria by ameliorating intraglomerular hypertension and tubulointerstitial fibrosis73,74, which are the two key contributors to renal damage in diabetic kidney disease (DKD).